Discover

RGLS
Regulus Therapeutics Inc.
8.16
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
timesize
Ytd416.46%
1y298.05%
8.16
day range
8.16
0.83
52 week range
8.35
Open8.16Prev Close8.16Low8.16High8.16Mkt Cap564.95M
Vol8.76MAvg Vol2.16MEPS-0.68P/E-12.00Forward P/E-1.26
Beta0.35Short Ratio3.38Inst. Own88.26%DividendN/ADiv YieldN/A
Ex Div DateN/AEarningN/A50-d Avg7.14200-d Avg2.891yr Est10.33

RGLS News

Novartis AGcompleted the acquisition of Regulus Therapeutics Inc..
https://www.marketscreener.com
Novartis AGcompleted the acquisition of Regulus Therapeutics Inc..

Novartis AG (SWX:NOVN) submitted a written non-binding indication of interest to acquire Regulus The

Novartis completes acquisition of Regulus Therapeutics
globenewswire.com
Novartis completes acquisition of Regulus Therapeutics

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition o

Novartis announces commencement of tender offer to acquire Regulus Therapeutics
globenewswire.com
Novartis announces commencement of tender offer to acquire Regulus Therapeutics

Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates
prnewswire.com
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

Entered into an agreement to be acquired by Novartis for $7.00 per share in cash, with potential to

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS
businesswire.com
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti,

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS
prnewswire.com
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. -

NEW YORK , April 30, 2025 /PRNewswire/ -- Monteverde & Associates PC  (the "M&A Class Action Firm"),

Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
benzinga.com
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednes

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
benzinga.com
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

Novartis AG NVS agreed to acquire Regulus Therapeutics Inc.  RGLS on Wednesday for an initial paymen

S&P 500 Falls 2%; Caterpillar Reports Downbeat Q1 Results
benzinga.com
S&P 500 Falls 2%; Caterpillar Reports Downbeat Q1 Results

RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders
businesswire.com
RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t

Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders
businesswire.com
Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Regulus (Nasdaq: RGLS) for possible brea

Novartis to buy Regulus Therapeutics for up to $1.7 billion
reuters.com
Novartis to buy Regulus Therapeutics for up to $1.7 billion

Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain acces

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
globenewswire.com
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to tr

Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Re

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
prnewswire.com
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.

Should You Buy Regulus (RGLS) After Golden Cross?
zacks.com
Should You Buy Regulus (RGLS) After Golden Cross?

Regulus Therapeutics Inc. (RGLS) reached a significant support level, and could be a good pick for i

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit
prnewswire.com
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

SAN DIEGO , April 2, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceuti

Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease
benzinga.com
Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare T

Regulus Therapeutics Inc. RGLS released topline results from all patients in the fourth cohort in it

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
prnewswire.com
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) C

Positive Topline Data from the Fourth Cohort of Patients Consistent demonstration of polycystin (PC)

4 Best Stocks To Buy Under $5
247wallst.com
4 Best Stocks To Buy Under $5

If you're one of the over 4 Million Americans set to retire this year, you may want to pay attention

What Makes Regulus (RGLS) a New Buy Stock
zacks.com
What Makes Regulus (RGLS) a New Buy Stock

Regulus (RGLS) might move higher on growing optimism about its earnings prospects, which is reflecte

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates
prnewswire.com
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

Positive topline results from an interim analysis of the fourth cohort of patients in the Phase 1b m

benzinga.com
Stocks That Hit 52-Week Lows On Monday

  On Monday, 198 companies hit new 52-week lows.

benzinga.com
Earnings Scheduled For March 9, 2023

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for

benzinga.com
Earnings Scheduled For November 10, 2022

Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings

benzinga.com
99 Biggest Movers From Yesterday

Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday a

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  During Wednesday's trading, 435 companies set new 52-week lows.

benzinga.com
Earnings Scheduled For May 13, 2021

  Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report

benzinga.com
Stocks That Hit 52-Week Highs On Wednesday

    This morning 194 companies reached new 52-week highs.

benzinga.com
Stocks That Hit 52-Week Highs On Tuesday

    On Tuesday, 596 companies set new 52-week highs.

benzinga.com
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Dec. 8, 2020: VBK, EXAS, TSM, AMC, RGLS

Today's 5 Stock Ideas:  Vanguard Small-Cap Growth Index ETF (VBK) - A way to gain exposure to

benzinga.com
Stocks That Hit 52-Week Highs On Thursday

Stocks That Hit 52-Week Highs On Thursday

benzinga.com
Stocks Which Set New 52-Week Low Yesterday, October 29th

Stocks Which Set New 52-Week Low Yesterday, October 29th

benzinga.com
Stocks Which Set New 52-Week Low Yesterday, October 22nd

Stocks Which Set New 52-Week Low Yesterday, October 22nd